GOTESSE Pharma & Biotech is pioneering a novel approach to malaria elimination by targeting the genetic drivers of Plasmodium falciparum resistance and persistent transmission. As resistance to artemisinin, the cornerstone of current malaria treatment, continues to spread, especially in sub-Saharan Africa, the need for innovative, complementary solutions has never been greater.
Through advanced genomic analysis and translational research, GOTESSE has developed artemisinin-free therapeutic candidates that offer a cost-effective, scalable alternative to current treatments. These interventions are designed to both mitigate emerging resistance and clear asymptomatic infections that sustain transmission, two critical gaps in existing malaria control strategies.
This breakthrough aligns with WHO’s Global Technical Strategy and supports broader global health goals by offering an evidence-based, locally accepted solution that strengthens and extends the impact of current antimalarial programs.
With strategic investment and policy support, GOTESSE’s innovation has the potential to accelerate malaria elimination efforts across Africa and beyond, delivering high-impact outcomes for health systems, communities, and future generations.
